Q-omics provides the consensus-scored SUMO2P18 profile across patient tissues and cancer cell-line models. SUMO2P18 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUMO2P18 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, SUMO2P18 RNA expression shows 6,600 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where SUMO2P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO2P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO2P18 survival associations across molecular data types. SUMO2P18 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO2P18 RNA expression–survival associations across cancer types. High SUMO2P18 expression shows unfavorable associations in KIRC, KICH, THCA, ACC and OV, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for SUMO2P18 RNA expression.
This table summarizes SUMO2P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SUMO2P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO2P18 shows lower tumor expression in THCA and BRCA and higher tumor expression in ESCA. The THCA box plot shows higher SUMO2P18 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with SUMO2P18 in patient tissues and cancer cell lines. In patient samples, SUMO2P18 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
